2019
DOI: 10.21037/apc.2019.09.01
|View full text |Cite
|
Sign up to set email alerts
|

Evolving trends in pancreatic cancer therapeutic development

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 114 publications
0
1
0
Order By: Relevance
“…Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer malignancies with a 5-year survival rate less than 10% with numbers that continue to rise steadily [ 1 3 ]. Of all pancreatic neoplasia PDAC is the most common type accounting for about 90% of pancreatic malignancies, mainly characterized by pronounced desmoplasia and morphologically altered duct stratification [ 2 , 4 ]. The often atypical symptoms that appear very late in the PDAC disease progression and the non-existing screening options for pancreatic cancer and its precursor lesions make early detection almost impossible [ 5 ].…”
Section: Introductionmentioning
confidence: 99%
“…Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancer malignancies with a 5-year survival rate less than 10% with numbers that continue to rise steadily [ 1 3 ]. Of all pancreatic neoplasia PDAC is the most common type accounting for about 90% of pancreatic malignancies, mainly characterized by pronounced desmoplasia and morphologically altered duct stratification [ 2 , 4 ]. The often atypical symptoms that appear very late in the PDAC disease progression and the non-existing screening options for pancreatic cancer and its precursor lesions make early detection almost impossible [ 5 ].…”
Section: Introductionmentioning
confidence: 99%